Original source text
Key Takeaways 10x Genomics shares rallied 84.1% in three months as consumables growth and Atera demand strengthened.TXG raised 2026 revenue guidance to $610M-$630M, with 2%-5% growth excluding patent settlements.10x Genomics' instrument revenue fell 47.2%, while its 11.9X forward sales multiple signals a premium. 10x Genomics, Inc. (TXG - Free Report) has surged 84% in the past three months, putting pressure on its fundamentals to keep pace with the stock. Consumables growth, Atera demand and a higher 2026 outlook provide support.
Weak instrument sales, operating losses and an elevated valuation leave less room for disappointment. Comparisons with genomics peers help frame whether TXG can sustain its recent lead.
TXG’s Consumables Momentum Strengthens the Growth CaseConsumables remain the steadier part of TXG’s business. Second-quarter 2026 consumables revenues increased 7% year over year, with Single Cell consumables up 3% as Flex Apex supported double-digit reaction-volume growth.
Spatial consumables rose 16%, primarily driven by Xenium. Recurring usage gives TXG a more durable revenue base than instrument placements, which remain sensitive to funding and capital-spending conditions.
Atera Could Extend TXG’s Spatial Biology OpportunityAtera adds another potential growth leg. Booked orders at the end of the second quarter already greatly exceeded TXG’s roughly 40-unit shipment plan for 2026, indicating strong early demand.
Near-term revenue conversion is constrained by manufacturing capacity, with most 2026 shipments expected in the fourth quarter. Customers are also moderating purchases of existing Spatial instruments before Atera arrives, creating a timing gap between demand and revenues.
How TXG Stacks Up Against ILMN and PACBIllumina, Inc. (ILMN - Free Report) offers a much larger-scale comparison. It reported second-quarter 2026 revenues of $1.16 billion, up 9.5% year over year, with a GAAP operating margin of 21.1%.
Pacific Biosciences of California, Inc. (PACB - Free Report) reported second-quarter revenues of $39.0 million compared with $39.8 million a year earlier, while consumables revenues increased to $20.1 million from $18.9 million. TXG’s recurring consumables growth stands out, but profitability and instrument demand remain key comparison points.
Image Source: Zacks Investment Research
TXG’s Raised Guidance Supports the RallyManagement raised 2026 revenue guidance to $610 million-$630 million from $600 million-$625 million. Excluding nonrecurring patent-settlement revenues in both periods, the updated range represents 2%-5% growth over 2025.
The outlook assumes the academic funding environment remains roughly consistent with recent conditions. The higher guidance therefore does not depend on a funding recovery, though better conditions could improve purchasing activity.
Image Source: Zacks Investment Research
Weak Instruments and Losses Keep Risk ElevatedSecond-quarter instrument revenues declined 47.2% year over year to $7.7 million. Single Cell instrument revenues fell 46.1%, while Spatial instrument revenues dropped 47.8%, reflecting fewer unit sales and the transition ahead of Atera.
TXG also recorded a $19.6 million operating loss despite gross margin reaching 74%. Stronger consumables demand has not yet translated into consistent operating leverage.
TXG’s Valuation Looks Demanding After the RallyTXG trades at 11.9X forward 12-month sales compared with 6.0X for its Zacks sub-industry and a five-year median of 6.3X. The stock therefore carries a sizable premium after its sharp advance.
That valuation raises the execution bar. Continued consumables growth and a smooth Atera ramp may be needed to support the premium as investors weigh TXG against ILMN and PACB.
Style Scores Favor Momentum More Than ValueThe bottom line is that TXG’s operating momentum has improved, but the 84.1% rally already reflects higher expectations. Atera demand and consumables trends provide support, while instrument weakness, losses and valuation limit the margin for error.
TXG currently carries a Zacks Rank #3 (Hold), with a Momentum Score of A, a Growth Score of B, a Value Score of F and a VGM Score of C. The scores favor momentum and growth characteristics more than value, while the Hold rank supports a balanced stance after the recent surge.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
|
Original source text
Key Takeaways 10x Genomics won over $4.8M after a jury found Parse willfully infringed three licensed patents.The jury upheld all three patents, reinforcing 10x Genomics' single-cell analysis IP portfolio.10x Genomics plans to seek enhanced damages, attorneys' fees and a permanent U.S. injunction. 10x Genomics, Inc. (TXG - Free Report) recently secured a favorable jury verdict in its patent infringement case against Parse Biosciences, a Qiagen (QGEN - Free Report) subsidiary. The Delaware jury found Parse infringed three patents licensed to Scale Biosciences, upheld the patents' validity and awarded damages to TXG.
From an investor's perspective, the ruling reinforces 10x Genomics' intellectual property position in the single-cell analysis market and could support additional financial recovery through post-trial proceedings. Investors will likely watch whether the company secures enhanced damages or further protections for its technology in the U.S. market.
Likely Trend of TXG Stock Following the NewsHowever, following the announcement, shares of TXG slipped more than 5% on Friday. Year to date, shares of the company have surged 277.4% compared with the industry’s 11.4% growth. However, the S&P 500 has risen 12.3% in the same timeframe.
In the long run, the verdict could strengthen 10x Genomics' competitive position by reinforcing the value of its single-cell sequencing intellectual property portfolio, a key differentiator in the genomics market. If the company secures enhanced damages or a permanent injunction in post-trial proceedings, it could discourage future infringement, protect market share and support continued investment in innovation across its expanding single-cell and spatial biology businesses.
TXG currently has a market capitalization of $8.02 billion.
Image Source: Zacks Investment Research
Details of the NewsThe U.S. District Court for the District of Delaware found that Parse Biosciences, now a Qiagen subsidiary, willfully infringed three patents exclusively licensed to Scale Biosciences, which became part of 10x Genomics in 2025. The patents, originally licensed from Roche Sequencing Solutions, cover foundational single-cell analysis technologies. Importantly, the jury rejected Parse's invalidity arguments and upheld the validity and enforceability of all three patents, strengthening 10x Genomics' intellectual property portfolio in the fast-growing genomics space.
The lawsuit centered on Parse's Evercode Whole Transcriptome products, with the jury concluding that infringing sales occurred from February 2021 through June 30, 2026. Based on a 14% royalty rate on those sales, the jury awarded more than $4.8 million in damages to 10x Genomics. The ruling follows a patent dispute that had been unfolding in Delaware federal court since 2022, making it one of the notable intellectual property battles in the single-cell sequencing market.
What's Next for Qiagen's Parse Business?The legal process is not over yet. In post-trial proceedings, 10x Genomics plans to seek enhanced damages, attorneys' fees and a permanent injunction that would prevent Parse from continuing to sell the infringing products in the United States. For Qiagen, the next phase of the case could determine whether Parse must modify its U.S. product strategy, secure licensing arrangements or pursue additional legal options as the court considers the requested remedies.
Industry Prospects Favoring the MarketPer a report by Custom Market Insights, the global spatial biology market size is estimated at $1.48 billion in 2026 and is anticipated to reach $7.24 billion by 2035, expanding at a CAGR of 19.2% from 2026 to 2035.
Growth in spatial biology is driven by the rising demand for single-cell and tissue-level insights to better understand complex diseases like cancer. Expanding use in drug discovery, precision medicine and AI-driven research, along with advances in high-throughput sequencing technologies, is accelerating market adoption.
Other NewsRecently, 10x Genomics exited the second quarter of 2026 with better-than-expected results, as both earnings and revenues beat the Zacks Consensus Estimate. Reported revenues declined year over year due to lower non-recurring license and royalty revenues. However, the underlying business remained resilient. Products and Services revenues increased, supported by growth in Single Cell and Spatial consumables and higher services revenues. Gross margin expansion was another positive, although the company swung to an operating loss from year-ago operating income.
Atera remained the key development in the quarter. Customer response was strong, with booked orders at the end of the second quarter already well above the roughly 40 instruments previously expected for 2026. TXG continues to expect shipments of around 40 units this year as manufacturing capacity ramps. The company expects Atera-related transition dynamics to weigh on third-quarter revenues as customers moderate purchases of existing Spatial products.
TXG’s Zacks Rank & Key PicksCurrently, TXG has a Zacks Rank #3 (Hold).
A couple of better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
|
Original source text
, /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today reported financial results for the second quarter ended June 30, 2026.
Recent Updates
Revenue was $151.0 million for the second quarter of 2026. Excluding $1.6 million related to a patent litigation settlement, revenue was $149.4 million. Revenue increased 3% over the corresponding period of 2025 when excluding non-recurring settlement revenue in both the current and prior-year periods. Acquired Proteintech Genomics, a division within Proteintech Group, strengthening the company's multiomics strategy by adding advanced protein detection capabilities to its single cell and spatial platforms. Announced multi-year research collaborations with Cleveland Clinic and Lausanne University Hospital to advance research in diagnostic applications of single cell and spatial technologies for cancer care, furthering the company's diagnostics strategy. "The story of the quarter was the extraordinary customer response to Atera. We are highly encouraged by the engagement across the research ecosystem and the very strong early order flow," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "Combined with the continued momentum across the rest of the business and our strong operating foundation, we are uniquely well-positioned for the opportunities ahead."
Second Quarter 2026 Financial Results
Revenue was $151.0 million for the second quarter of 2026, as compared to $172.9 million for the corresponding period of 2025. Excluding $1.6 million and $27.3 million of non-recurring revenue related to patent litigation settlements in the second quarter of 2026 and 2025, respectively, revenue increased 3% over the corresponding period of 2025.
Gross margin was 74% for the second quarter of 2026, as compared to 72% for the corresponding prior year period. The increase in gross margin was primarily due to lower manufacturing costs, which included $2.6 million of tariff refunds, as well as lower inventory write-downs, partially offset by a decrease in non-recurring license and royalty revenue.
Operating expenses were $132.1 million for the second quarter of 2026, a 39% increase from $95.0 million for the corresponding prior year period. The increase was primarily due to a lower gain on settlement of $3.4 million recognized in the second quarter of 2026, as compared to a $40.7 million gain on settlement recognized in the second quarter of 2025. Excluding impacts from settlements, operating expenses were approximately flat year-over-year.
Operating loss was $19.6 million for the second quarter of 2026, as compared to operating income of $30.1 million for the corresponding prior year period.
Net loss was $17.9 million for the second quarter of 2026, as compared to net income of $34.5 million for the corresponding prior year period.
Cash and cash equivalents and marketable securities were $552.0 million as of June 30, 2026.
2026 Financial Guidance
10x Genomics is raising its full year 2026 revenue guidance and now expects revenue in the range of $610 million to $630 million, versus the previous range of $600 million to $625 million. Excluding the non-recurring license and royalty revenue related to patent litigation settlements in both 2026 and 2025, this represents 2% to 5% growth over full year 2025.
Webcast and Conference Call Information
10x Genomics will host a conference call to discuss the second quarter 2026 financial results, business developments and outlook after market close on Thursday, August 6, 2026 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. A webcast of the conference call can be accessed at http://investors.10xgenomics.com. The webcast will be archived and available for replay at least 45 days after the event.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "outlook," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s products, services, business strategy, collaborations and opportunities and 10x Genomics, Inc.'s financial performance and results of operations, including expectations regarding revenue and guidance. These statements are based on management's current expectations, forecasts, beliefs, estimates, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K for the fiscal year ended December 31, 2025 filed on February 12, 2026 and the company's quarterly report on Form 10-Q for the quarter ended June 30, 2026 to be filed with the U.S. Securities and Exchange Commission ("SEC"), and elsewhere in the documents 10x Genomics, Inc. files with the SEC from time to time.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Contacts
Investors: [email protected]
Media: [email protected]
10x Genomics, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except share and per share data)
Three Months Ended
June 30,
Six Months Ended
June 30,
2026
2025
2026
2025
Products and services revenue
$ 149,094
$ 145,157
$ 298,990
$ 282,980
License and royalty revenue
1,942
27,751
2,889
44,811
Revenue (1)
151,036
172,908
301,879
327,791
Cost of products and services revenue (2)
38,539
47,824
83,204
97,262
Gross profit
112,497
125,084
218,675
230,529
Operating expenses:
Research and development (2)
56,791
61,224
113,638
125,469
Selling, general and administrative (2)
78,661
74,434
145,038
164,162
Gain on settlement
(3,400)
(40,700)
(3,400)
(49,900)
Total operating expenses
132,052
94,958
255,276
239,731
Income (loss) from operations
(19,555)
30,126
(36,601)
(9,202)
Other income (expense):
Interest income
4,797
4,271
9,811
7,957
Interest expense
—
(3)
—
(3)
Other income (expense), net
(3,887)
2,603
(4,702)
4,739
Total other income
910
6,871
5,109
12,693
Income (loss) before provision for income taxes
(18,645)
36,997
(31,492)
3,491
Provision for (benefit from) income taxes
(714)
2,459
(91)
3,311
Net income (loss)
$ (17,931)
$ 34,538
$ (31,401)
$ 180
Net income (loss) per share, basic
$ (0.14)
$ 0.28
$ (0.24)
$0.00
Net income (loss) per share, diluted
$ (0.14)
$ 0.28
$ (0.24)
$0.00
Weighted-average shares used to compute net income
(loss) per share, basic
129,984,169
123,755,409
129,050,312
123,183,924
Weighted-average shares used to compute net income
(loss) per share, diluted
129,984,169
124,509,720
129,050,312
124,258,150
(1)
The following table represents total revenue by source for the periods indicated (in thousands). Spatial includes the Company's Visium and Xenium products:
Three Months Ended
June 30,
Six Months Ended
June 30,
2026
2025
2026
2025
Instruments
Single Cell
$ 3,087
$ 5,727
$ 8,310
$ 11,640
Spatial
4,574
8,770
$ 10,613
17,672
Total instruments revenue
7,661
14,497
18,923
29,312
Consumables
Single Cell
88,451
85,788
177,345
169,897
Spatial
42,301
36,397
83,208
67,644
Total consumables revenue
130,752
122,185
260,553
237,541
Services
10,681
8,475
19,514
16,127
Products and services revenue
149,094
145,157
$ 298,990
$ 282,980
License and royalty revenue
1,942
27,751
$ 2,889
$ 44,811
Total revenue
$ 151,036
$ 172,908
$ 301,879
$ 327,791
(1)
The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):
Three Months Ended
June 30,
Six Months Ended
June 30,
2026
2025
2026
2025
Americas
United States*
$ 82,109
$ 103,491
$ 158,802
$ 190,309
Americas (excluding United States)
2,917
2,667
$ 6,323
6,419
Total Americas
85,026
106,158
165,125
196,728
Europe, Middle East and Africa
39,972
34,734
76,824
66,629
Asia-Pacific
China
14,968
23,170
30,805
40,053
Asia-Pacific (excluding China)
11,070
8,846
29,125
24,381
Total Asia-Pacific
26,038
32,016
59,930
64,434
Total revenue
$ 151,036
$ 172,908
$ 301,879
$ 327,791
* Includes license and royalty revenue.
(2)
Includes stock-based compensation expense as follows:
Three Months Ended
June 30,
Six Months Ended
June 30,
(in thousands)
2026
2025
2026
2025
Cost of revenue
$ 1,836
$ 1,989
$ 3,754
$ 4,470
Research and development
10,533
12,613
21,228
26,719
Selling, general and administrative
13,247
12,643
23,276
27,132
Total stock-based compensation expense
$ 25,616
$ 27,245
$ 48,258
$ 58,321
10x Genomics, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In thousands)
June 30,
2026
December 31,
2025
Assets
Current assets:
Cash and cash equivalents
$ 502,512
$ 473,966
Marketable securities
49,521
49,443
Accounts receivable, net
47,545
47,013
Other receivables
3,084
35,480
Inventory
52,616
56,341
Prepaid expenses and other current assets
19,393
22,208
Total current assets
674,671
684,451
Property and equipment, net
215,324
226,711
Operating lease right-of-use assets
56,685
60,450
Goodwill
6,918
4,511
Intangible assets, net
61,160
62,329
Other noncurrent assets
15,308
2,913
Total assets
$ 1,030,066
$ 1,041,365
Liabilities and stockholders' equity
Current liabilities:
Accounts payable
$ 20,694
$ 12,733
Accrued compensation and related benefits
24,744
42,500
Accrued expenses and other current liabilities
30,377
39,971
Deferred revenue
23,610
23,902
Operating lease liabilities
12,015
10,985
Contingent consideration, current
7,069
23,363
Total current liabilities
118,509
153,454
Contingent consideration, noncurrent
2,991
1,237
Operating lease liabilities, noncurrent
66,781
73,376
Deferred revenue, noncurrent
9,683
10,501
Other noncurrent liabilities
6,556
6,471
Total liabilities
204,520
245,039
Stockholders' equity:
Preferred stock
—
—
Common stock
2
2
Additional paid-in capital
2,367,459
2,306,690
Accumulated deficit
(1,541,992)
(1,510,591)
Accumulated other comprehensive income
77
225
Total stockholders' equity
825,546
796,326
Total liabilities and stockholders' equity
$ 1,030,066
$ 1,041,365
SOURCE 10x Genomics, Inc.
|
Original source text
Wall Street expects a year-over-year decline in earnings on lower revenues when 10x Genomics (TXG - Free Report) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on August 6. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus EstimateThis life science technology company is expected to post quarterly loss of $0.23 per share in its upcoming report, which represents a year-over-year change of -182.1%.
Revenues are expected to be $146.96 million, down 15% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 1.73% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for 10x Genomics?For 10x Genomics, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +10.93%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination indicates that 10x Genomics will most likely beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that 10x Genomics would post a loss of$0.29 per share when it actually produced a loss of -$0.10, delivering a surprise of +65.52%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
10x Genomics appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Expected Results of an Industry PlayerCarlsmed, Inc. (CARL - Free Report) , another stock in the Zacks Medical Info Systems industry, is expected to report loss per share of $0.4 for the quarter ended June 2026. This estimate points to a year-over-year change of +72.8%. Revenues for the quarter are expected to be $18.52 million, up 53.3% from the year-ago quarter.
The consensus EPS estimate for Carlsmed, Inc. has remained unchanged over the last 30 days. However, a lower Most Accurate Estimate has resulted in an Earnings ESP of -18.99%.
When combined with a Zacks Rank of #3 (Hold), this Earnings ESP makes it difficult to conclusively predict that Carlsmed, Inc. will beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
|
Original source text
Collaboration aims to identify biomarkers predictive of treatment response across multiple cancer types using 10x's single cell and spatial platforms
, /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a research collaboration with Lausanne University Hospital (CHUV), one of Switzerland's leading academic medical centers, to advance research in diagnostic applications of single cell and spatial technologies for cancer care.
This collaboration builds on 10x's broader efforts to work with leading research institutions to generate the scientific evidence needed to advance future diagnostic applications of single cell and spatial technologies.
Through this multi-year collaboration, the study intends to use 10x's Flex Apex and Xenium platforms, with the goal of expanding to the Atera platform, to examine tumor samples from patients with advanced cancer undergoing a comprehensive evaluation by a clinical molecular tumor board. The research aims to identify clinically relevant biomarkers that may help predict treatment response, cancer prognosis and support diagnostic development.
The rapid expansion of targeted therapies, immunotherapies and other emerging treatment modalities is creating new opportunities for treating patients, while also increasing the complexity of treatment decision-making in oncology. As a result, there is a growing need for biomarkers that can help predict which patients are most likely to benefit from specific therapies, supporting more personalized treatment strategies.
"This collaboration brings together complementary expertise in spatial biology, pathology, computational AI and clinical precision oncology to address one of the biggest challenges in cancer care: predicting which patients will benefit from treatment," said Raphael Gottardo, Professor and Director of the Biomedical Data Science Center, CHUV. "Together, we aim to discover clinically actionable biomarkers that improve patient selection and bring more precise treatment decisions closer to routine clinical care."
The study is expected to include hundreds of patients across multiple solid tumor types, including non-small cell lung cancer, breast cancer, bladder cancer and melanoma. Researchers plan to integrate single cell and spatial biology with clinical outcomes data to better understand mechanisms of response and resistance across a range of therapeutic approaches, including antibody-drug conjugates, bispecific antibodies and immune checkpoint inhibitors. The collaboration also intends to investigate how 10x single cell and spatial technologies can be deployed clinically alongside current standard-of-care assays.
"The promise of precision oncology depends on understanding the biology that helps determine which therapies are most likely to benefit a given patient," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "We believe single cell and spatial technologies provide a fundamentally richer view of the biology within tumors and their microenvironment, creating opportunities to discover biomarkers that can help guide treatment decisions and enable future diagnostic approaches in cancer care."
The collaboration is expected to generate a comprehensive, multimodal resource integrating single cell and spatial data to enable the discovery of clinically actionable biomarkers of treatment response and resistance. It also plans to evaluate how these biomarkers could be incorporated into future clinical reporting frameworks to support personalized treatment planning and molecular tumor board decision-making.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.
About Lausanne University Hospital (CHUV)
Lausanne University Hospital (CHUV) is one of Switzerland's leading academic medical centers, uniting clinical excellence, biomedical research, and medical education under one roof. Consistently ranked among the world's best hospitals by Newsweek, CHUV also serves as a think tank driving forward research and medicine – bringing together clinicians, pathologists, computational scientists, and translational researchers to accelerate the development of precision medicine. Through multidisciplinary programs spanning cancer research, advanced imaging, digital pathology, artificial intelligence, and spatial biology, CHUV is pioneering next-generation biomarkers and diagnostics – improving patient outcomes and enabling more personalized treatment decisions. To learn more, visit https://www.chuv.ch or connect with us on LinkedIn, Facebook, Instagram, YouTube.
Contacts
Investors: [email protected]
Media: [email protected]
SOURCE 10x Genomics, Inc.
|
Original source text
Key Takeaways 10x Genomics is collaborating with the Cleveland Clinic on bladder cancer diagnostic applications.The study will use Flex Apex and Xenium to find biomarkers tied to treatment response.The partnership could expand 10x Genomics' role in precision oncology and diagnostics. 10x Genomics (TXG - Free Report) recently entered into a multi-year research collaboration with the Cleveland Clinic to advance novel diagnostic applications for bladder cancer. The study will use the company's Flex Apex and Xenium platforms, with potential expansion to Atera, to identify biomarkers that may predict patient response to antibody-drug conjugates and immunotherapies.
From an investor's perspective, the collaboration marks another step in 10x Genomics' strategy to expand its technologies into clinical and diagnostic applications. The partnership could strengthen the company's position in precision oncology, broaden the use cases for its single-cell and spatial platforms and create long-term growth opportunities in cancer diagnostics.
Likely Trend of TXG Stock Following the NewsShares of TXG have traded flat since the announcement on Wednesday. In the year-to-date period, shares of the company surged 113.1% against the industry’s 20.1% decline. The S&P 500 increased 8.5% in the same time frame.
The collaboration with Cleveland Clinic is likely to strengthen 10x Genomics' long-term growth prospects by generating clinical evidence for the use of its single-cell and spatial technologies in precision oncology. Successful identification of predictive biomarkers could accelerate the adoption of Flex Apex, Xenium and Atera in translational research and future diagnostic applications, expand the company's presence in the high-growth oncology diagnostics market and create new revenue opportunities beyond its core research business.
TXG currently has a market capitalization of $4.08 billion.
Image Source: Zacks Investment Research
More on the NewsUnder the multi-year collaboration, 10x Genomics and the Cleveland Clinic are likely to initially analyze tumor samples from patients with advanced bladder cancer undergoing emerging therapeutic regimens. The study is likely to leverage TXG's Flex Apex and Xenium platforms and could later expand to the recently launched Atera platform. The partners aim to identify clinically relevant biomarkers that may predict patient responses to antibody-drug conjugates and immunotherapies, paving the way for future diagnostic development across multiple tumor types.
The research is likely to integrate single-cell transcriptomic profiling with spatial gene expression and protein measurements to generate a comprehensive view of tumor biology and the tumor microenvironment. Investigators are likely to assess tumor microenvironment composition, immune cell infiltration and the expression of therapeutic targets to better understand mechanisms underlying treatment response and resistance.
The collaboration is expected to generate a rich multimodal dataset linking molecular insights with clinical outcomes, supporting the development of next-generation precision oncology diagnostics and advancing the scientific understanding of bladder cancer.
Favorable Industry Prospect for TXGPer a report by Precedence Research, the global bladder cancer therapeutics diagnostics market size accounted for $5.68 billion in 2025 and is predicted to increase from $6.01 billion in 2026 to approximately $10.04 billion by 2035, expanding at a CAGR of 5.86%.
The bladder cancer diagnostics market is expanding rapidly, driven by the rising prevalence and awareness of the disease, alongside advances in precision medicine, personalized treatment approaches and non-invasive diagnostic technologies.
A Recent Development by TXGRecently, 10x Genomics announced the acquisition of Proteintech Genomics, a division within Proteintech Group that develops high-plex proteomic solutions for single-cell and spatial biology applications. The move expands TXG's capabilities in proteomics and supports its broader strategy of advancing multiomics research through integrated RNA and protein analysis.
Proteintech Genomics brings technologies, including the Human Discovery Panel, an antibody-based single-cell protein panel compatible with 10x Genomics' Flex chemistry workflows.
TXG’s Zacks Rank & Key PicksCurrently, TXG carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12 per share, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
West Pharmaceutical, currently flaunting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.
WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
ISRG has a long-term estimated growth rate of 14.6% compared with the industry’s 12.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
|
